Nilotinib-d6 – 1 mg

Brand:
Cayman
CAS:
1268356-17-7
Storage:
-20
UN-No:
Non-Hazardous - /

Nilotinib-d6 contains three deuterium atoms located on the phenyl group and three deuterium atoms located on the methyl group. It is intended for use as an internal standard for the quantification of nilotinib (Item No. 10010422) by GC- or LC-MS. Nilotinib is a second generation tyrosine kinase inhibitor that potently inhibits Bcr/Abl tyrosine kinase and is effective in the treatment of chronic myeloid leukemia (MLL) or Philadelphia chromosome acute lymphoblastic leukemia (Ph+ ALL), even in patients who are resistant to the first generation drug, imatinib (Gleevec; Item Nos. 13139 | 18257).{17486,17480,17482,17483} Nilotinib is ~20-fold more potent than imatinib in inhibiting both wild-type and mutant Bcr/Abl (e.g., IC50 = 15 versus 280 nM, respectively, for wild-type Bcr/Abl).{17481}  

 

Available on backorder

SKU: - Category:

Description

An internal standard for the quantification of nilotinib by GC- or LC-MS


Formal name: 4-(methyl-d3)-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide-2,3,6-d3

Synonyms: 

Molecular weight: 535.6

CAS: 1268356-17-7

Purity: ≥99% deuterated forms (d1-d6)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Kinase Inhibitors|Abl Family & Bcr-Abl||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Abl family & Bcr-Abl Signaling